Following a phase 1b trial, the potent and selective dual inhibitor of IRAK1 and IRAK4 received fast track designation for the treatment of patients with lower-risk myelodysplastic syndrome.
According to the American Lung Association, biomarker testing gaps and low screening rates continue to hinder lung cancer ...
The FDA approved a companion diagnostic to identify patients with biliary tract cancer eligible for treatment with ...
Oncology nurses “play a pivotal role in guiding patients” through the genetic testing process, an expert explained.
Most patients with triple-negative breast cancer experienced a protocol-defined immune response with an investigational vaccine, phase 1 data showed. More than 70% of patients with triple-negative ...
Novel Drug Combo Is Promising for PD-L1-Resistant Solid Cancers ...
The FDA received a biologics license application for accelerated approval of RP1 plus nivolumab for advanced, pretreated ...
The FDA accepted a supplemental new drug application to darolutamide plus androgen deprivation therapy for metastatic hormone ...
Novel Drug Combo Is Promising for PD-L1-Resistant Solid Cancers ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback